AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted a dedicated event aimed at improving outcomes for patients living with cardiovascular, renal, and metabolic (CRM) ...
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
October 10, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading ... GoodRx announced a new partnership with Boehringer Ingelheim to provide discounts for a ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
Today, GoodRx , the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormone therapies by Pfizer. Through the reach and scale ...
Boehringer Ingelheim says it is on track to launch ... R&D pipeline that it says is the best in its 139-year history. The company expects to start around 10 new phase 2 and 3 trials within the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback